Fierce Pharma

Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's Rybrevant

Watch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure ...
pharmaphorum

Dizal breaks new ground for EGFR drugs in lung cancer

Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...
Monthly Prescribing Reference

Rybrevant Combo Approved as First-Line Tx for NSCLC With EGFR Exon 20 Insertion Mutations

Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
The American Journal of Managed Care

Marcia Horn Discusses Advancements in EGFR Exon 20 Insertion+ NSCLC and the Importance of Community

There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access ...
MedPage Today

Oral Targeted Therapy for Exon 20 Insertions in NSCLC Wins FDA Accelerated Approval

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said.